Skip to main content

Advertisement

SpringerLink
Log in

Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma

  • Original Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

A Correction to this article was published on 24 April 2018

This article has been updated

Abstract

Objective

Our previous differential transcriptome analysis between a paired specimen of normal and esophageal squamous cell carcinoma (ESCC) tissues found aberrant expression of kallikrein-related peptidase 13 (KLK13) in tumors. In this study, we evaluated the expression of KLK13 in many ESCC cases in relation with clinical features, and the prognosis.

Methods

Eighty-eight ESCC cases were subjected to immunohistological staining for KLK13 and classified into KLK13-negative and KLK13-positive groups. Difference of clinical features and the prognosis between the groups was analyzed.

Results

In normal esophageal mucosa, KLK13 expression was evident but limited in the stratum granulosum in all cases. By contrast, only 27 of 88 ESCC samples showed KLK13 expression, whereas the remaining 61 tumors showed no KLK13 expression. The KLK13-positive group was significantly associated with pT classification (deeper tumor invasions; P = 0.0282), pN classification (lymph node metastasis; P = 0.0163), and advanced TNM stage (P = 0.0198). In KLK13-positive samples, KLK13-expressing cells often expressed Ki67, a proliferation marker, unlike normal mucosa, in which Ki67-expressing cells were limited to the basal layer and did not express KLK13. Compared with patients with KLK13-negative group, KLK13-positive group showed poorer postoperative prognosis.

Conclusion

Relatively high levels of KLK13 expression in ESCC were associated with cell proliferation and correlated with tumor progression, advanced cancer stage, and poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 24 April 2018

    In the original publication of the article, Fig. 1 was published incorrectly.

References

  1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.

    Article  PubMed  Google Scholar 

  2. Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus. 2017;14:189–214.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008;2:85–92.

    PubMed  PubMed Central  Google Scholar 

  4. Ikebe M, Morita M, Yamamoto M, Toh Y. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. Gen Thorac Cardiovasc Surg. 2016;64:386–94.

    Article  PubMed  Google Scholar 

  5. Otsubo T, Yamada K, Hagiwara T, Oshima K, Iida K, Nishikata K, et al. DNA hypermethylation and silencing of PITX1 correlated with advanced stage and poor postoperative prognosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8:84434–48.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med. 2012;50:1877–91.

    Article  PubMed  CAS  Google Scholar 

  7. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer. 2009;100:1659–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Borgono CA, Diamandis EP. The emerging roles of human kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90.

    Article  PubMed  CAS  Google Scholar 

  9. Yousef GM, Chang A, Diamandis EP. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 2000;275:11891–8.

    Article  PubMed  CAS  Google Scholar 

  10. Tokas T, Avgeris M, Alamanis C, Scorilas A, Stravodimos KG, Constantinides CA. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients’ prognosis. J Cancer Res Clin Oncol. 2017;143:521–32.

    Article  PubMed  CAS  Google Scholar 

  11. Ishige S, Kasamatsu A, Ogoshi K, Saito Y, Usukura K, Yokoe H, et al. Decreased expression of kallikrein-related peptidase 13: possible contribution to metastasis of human oral cancer. Mol Carcinog. 2014;53:557–65.

    Article  PubMed  CAS  Google Scholar 

  12. Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, et al. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol Rep. 2014;31:1883–90.

    Article  PubMed  CAS  Google Scholar 

  13. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponnzone R, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer. 2002;86:1457–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Doré JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009;101:1107–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Planque C, Bléchet C, Ayadi-Kaddour A, Heuzé-Vourc’h N, Dumont P, Guyétant S, et al. Quantitative RT-PCR analysis and immunohistochemical localization of the lkallikrein-related peptidase 13 and 14 in lung. Biol Chem. 2008;389:781–6.

    Article  PubMed  CAS  Google Scholar 

  16. Chou RH, Lin SC, Wen HC, Wu CW, Chang WS. Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun. 2011;409:442–7.

    Article  PubMed  CAS  Google Scholar 

  17. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem. 2003;49:77–86.

    Article  PubMed  CAS  Google Scholar 

  18. Tarhoni I, Fhied CL, Pool M, Liptay MJ, Bonomi P, Deder CW, et al. Development of bead based multiplex immunoassay for evaluation of midkine, syndecan-1, ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018;39:84–98.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. Miwa Tamura-Nakano and Chinatsu Oyama in NCGM EM Support Unit for their technical support for histological analysis. We also thank Ms. Yasuko Nozaki for her technical assistance. This work was supported by JSPS KAKENHI Grants Numbers JP15K10124, JP15H04503, JP16K09299, and by grants from the National Center for Global Health and Medicine (26–110, 26–117, 27-1406, 29-1008, 29-1013, 29-1019, and 29-1029).

Author information

Author notes

  1. Leo Yamada

    Present address: Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan

Authors and Affiliations

  1. Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan

    Kyoko Nohara, Kazuhiko Yamada, Leo Yamada, Daisuke Soma & Satoshi Yamashita

  2. Department of Gastroenterology, The Research Center for Hepatitis and Immunology, Research Institute, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, 272-8516, Japan

    Teruki Hagiwara, Taeko Dohi & Yuki I. Kawamura

  3. Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan

    Toru Igari

  4. Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan

    Chizu Yokoi

Authors
  1. Kyoko Nohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiko Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leo Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruki Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toru Igari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chizu Yokoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisuke Soma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Taeko Dohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuki I. Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuki I. Kawamura.

Ethics declarations

Conflict of interest

All authors have no financial or other relations that could lead to a conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nohara, K., Yamada, K., Yamada, L. et al. Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg 66, 351–357 (2018). https://doi.org/10.1007/s11748-018-0910-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-018-0910-5

Keywords

Search

Navigation